Researchers studied 1,866 postmenopausal women and found that using bisphosphonate for more than one year helped reduce the risk of colorectal cancer by 59 percent. The bisphosphonate used by a majority of women was alendronate, sold under the brand name Fosamax and made available under a generic brand. The positive effect of taking bisphosphonate after the one-year mark was not as significant, according to the report.
Read the news report about bisphosphonate and CRC.
Read other coverage about colorectal cancer:
– 10 Recent Findings on GI Quality Issues
– Pricetag of Treating CRC: $14.1B
– USPSTF Advises Against CRC Screening for Individuals Older Than 85
